InvestmentMay 12, 2026, 04:23 PM
Sunshine Biopharma Files S-1 for $6M Public Offering
AI Summary
Sunshine Biopharma Inc. filed an S-1 registration statement for a public offering of up to $6,000,000 in common units and pre-funded units. Each common unit consists of one share of common stock and two Series C Warrants, while pre-funded units include a pre-funded warrant and two Series C Warrants. The company expects to receive approximately $5.0 million in net proceeds, which will be used for general corporate purposes, including working capital. The offering is on a best efforts basis with no minimum amount required to close, and involves significant dilution for existing shareholders.
Key Highlights
- Offering up to $6,000,000 in common units and pre-funded units.
- Up to 5,825,242 common units, each with one common stock share and two Series C Warrants.
- Series C Warrants have an initial exercise price of $1.03 per share, exercisable for five years.
- Pre-funded units offered to limit beneficial ownership to 4.99% (or 9.99%).
- Pre-funded warrants have a nominal exercise price of $0.00001 per share.
- Estimated net proceeds of approximately $5.0 million after fees and expenses.
- Common stock outstanding before offering: 5,005,945 shares as of May 11, 2026.
- Pro forma common stock outstanding after offering: 10,831,187 shares.
Price Impact
More from SBFM